BioSante Pharmaceuticals, Inc. and Rodman & Renshaw Announce Fireside Chat on Women’s Health
LINCOLNSHIRE, Illinois (March 18, 2010) – BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) and Rodman & Renshaw (NASDAQ: RODM) today announced that Rodman will host Stephen M. Simes, CEO of BioSante, for a fireside chat in Rodman’s media center, on March 24, 2010. The event will be moderated by Elemer Piros, Ph.D., senior biotechnology analyst at Rodman & Renshaw, LLC. The topics to be covered will include an overview of BioSante and specifically LibiGel® (testosterone gel) in development for the treatment of female sexual dysfunction, as well as BioSante’s portfolio of cancer vaccines.
The presentation will take place at the Rodman & Renshaw Offices (1251 Avenue of the Americas, 20th Floor, New York, NY 10020) at 4:30PM ET on March 24, 2010. To attend, please RSVP to Aryea Aranoff at email@example.com. Please respond quickly as space is limited. Password: BioSante, and it will be broadcast via conference call at the following dial-In Number: (888) 211-4434 or for international callers: (913) 312-0674, Passcode: 6038945.
About Rodman & Renshaw
Rodman & Renshaw, LLC is a full-service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. Rodman also provides research and sales and trading services to institutional investors. Rodman is the leader in the PIPE (private investment in public equity) and RD (registered direct offering) transaction markets and has been ranked the #1 Placement Agent in terms of the aggregate number of PIPE and RD financing transactions completed every year since 2005 according to Sagient Research Systems
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. BioSante’s lead products include LibiGel® (transdermal testosterone gel) in Phase III clinical development by BioSante under a U.S. Food and Drug Administration (FDA) SPA (Special Protocol Assessment) for the treatment of female sexual dysfunction (FSD), and Elestrin™ (estradiol gel) developed through FDA approval by BioSante, indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, currently marketed in the U.S.
Also in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, licensed to Teva Pharmaceuticals (NASDAQ: TEVA) and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3 billion. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook™), as a vaccine adjuvant, including for an H1N1 (swine flu) vaccine, and drug delivery. In addition, BioSante will seek opportunities for its GVAX cancer immunotherapies, 2A/Furin and other technologies. Additional information is available online at: biosantepharma.cdmail.biz.
For more information please contact:
Harris D. McKinney, Inc.
For information about participating in the LibiGel clinical studies call or visit the following: